Recent studies have highlighted EVs‐based vaccines' efficacy, biocompatibility, and safety against COVID‐19.[209] The study proved the effectiveness of exosomes for inhalation and showed superior immunological advantages, allowing for faster clearance of the virus.[210] In fact, EV‐ACE2 was 60‐ to 80‐fold more effective in preventing pseudotyped and true SARS‐CoV‐2 infections compared to vesicle‐free recombinant human ACE2 (rhACE2).[211] With the passing of the COVID‐19 pandemic, This EVs‐based viral vaccine is critical in the preventive role of other viruses. The gene discussed is ACE2; the disease is COVID-19.